MNOV Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
138.6K
-69.8%
458.4K
+145.2%
187.0K
+23.2%
151.7K
+23.0%
123.3K
Cost of Revenue
0
0
0
0
0
Gross Profit
138.6K
-69.8%
458.4K
+145.2%
187.0K
+23.2%
151.7K
+23.0%
123.3K
Operating Expenses
3.2M
+6.6%
3.0M
-0.8%
3.0M
-6.8%
3.2M
-7.4%
3.5M
R&D
1.2M
+21.3%
1.0M
-18.5%
1.3M
-18.2%
1.5M
-2.5%
1.6M
SG&A
1.9M
-1.0%
2.0M
+11.9%
1.8M
+3.5%
1.7M
-11.5%
1.9M
Operating Income
-3060224
-20.4%
-2541189
+10.4%
-2835806
+8.3%
-3092402
+8.5%
-3380998
EBITDA
-3056805
-20.5%
-2536169
+10.4%
-2831546
+8.3%
-3087847
+8.5%
-3375695
Net Income
-2842962
-22.9%
-2314139
+10.5%
-2586258
+7.7%
-2802279
+8.1%
-3050373
EPS (Basic)
$-0.06
-20.0%
$-0.05
+0.0%
$-0.05
+16.7%
$-0.06
+0.0%
$-0.06
EPS (Diluted)
$-0.06
-20.0%
$-0.05
+0.0%
$-0.05
+16.7%
$-0.06
+0.0%
$-0.06
Shares (Diluted)
49.4M
+0.3%
49.2M
+0.0%
49.2M
+0.2%
49.1M
+0.1%
49.0M
Medicinova (MNOV) — Financials